Guides
Research Guides
Evidence-first frameworks for reading clinical endpoints, FDA milestones, and biotech licensing economics without overreading a headline.
Clinical Endpoints
Clinical endpoints define what a trial is trying to prove. For investors and industry readers, the key question is not only whether a p-value is positive, but whether the endpoint reflects meaningful patient benefit, regulatory relevance, and commercial differentiation.
Regulatory Milestones
IND clearance, Phase II data, pivotal trial design, NDA/BLA submission, advisory committees, and approval decisions each change the evidence package in different ways. Good analysis asks what uncertainty has been reduced, and what risk remains.
BD and Licensing Terms
Upfront payments, milestones, royalties, option structures, territory rights, and development responsibilities reveal how partners allocate risk and value. The headline number is rarely the full story.